Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Immunocytokines: A new approach to immunotherapy of melanoma

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Reisfeld, Ralph
  • Becker, J. C.
  • Gillies, S. D.

publication date

  • 1997

journal

  • Melanoma Research  Journal

abstract

  • Targeted interleukin-2 (IL-2) therapy with immunocytokines (i.e. antibody-cytokine fusion proteins) is effective in eradicating established hepatic and pulmonary metastases of melanoma in animal model systems. The effector mechanisms responsible for this antitumor effect in syngeneic, immunocompetent mice involves mainly CD8+ T cells. This was clearly indicated by immunohistochemical analyses, in vivo depletion studies and cytotoxicity tests. Such CD8+ T cells, isolated from tumor-bearing mice after immunocytokine therapy, exerted a major histocompatibility complex class I-restricted cytotoxicity against the same tumor in vitro. Because of this cellular immune response, antibody-directed IL-2 therapy can even address established metastases displaying extensive heterogeneity in the expression of the targeted antigen. The effector mechanisms induced by immunocytokines facilitate partial regressions of large subcutaneous melanoma exceeding more than 5% of the body weight. These results demonstrate the ability of immunocytokines to induce a T-cell-dependent host immune response capable of eradicating established melanoma metastases in clinically relevant organs and offers an effective, new tool for immunotherapy of malignant melanoma.

subject areas

  • Animals
  • Cytokines
  • Humans
  • Immunotherapy
  • Immunotoxins
  • Interleukin-2
  • Melanoma
  • Mice
  • T-Lymphocytes
scroll to property group menus

Research

keywords

  • immunocytokines
  • melanoma
  • targeted interleukin-2 therapy
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0960-8931

PubMed ID

  • 9578424
scroll to property group menus

Additional Document Info

start page

  • S99

end page

  • S106

volume

  • 7

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support